

AMENDMENTS TO THE CLAIMS

Claim 1. (Previously presented) The isolated peptide sequence GGIGDGG (SEQ ID NO:2).

Claim 2. (Currently amended) An angiogenic composition comprising ~~at least one peptide including the isolated peptide~~ sequence GGIGDGG (SEQ ID NO:2), and at least one angiogenic ~~growth factor peptide~~ other than said ~~at least one~~ peptide.

Claim 3. (Currently amended) The angiogenic composition of claim 2 wherein said other at least one angiogenic ~~growth factor peptide~~ is chosen from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF- α), transforming growth factor-beta (TGF- β), and tumor necrosis factor-alpha (TNF- α).

Claim 4. (Currently amended) The angiogenic composition of claim 2 wherein ~~said at least one said other at least one~~ angiogenic ~~growth factor peptide comprises~~ is a recombinant angiogenic ~~growth factor peptide~~.

Claim 5. (Currently amended) A composition that is active for promoting cell migration and/or angiogenesis under cell growth promoting conditions, the composition comprising ~~at least one peptide including~~ the isolated peptide sequence GGIGDGG (SEQ ID NO:2), and a matrix material.

Claim 6. (Currently amended) The composition of claim 5, further comprising a pharmacologically acceptable carrier.

Claims 7-19. (Canceled)

Claim 20. (Currently amended) The angiogenic composition of claim 2 wherein said other at least one angiogenic ~~growth-factor~~ peptide comprises bone-derived angiogenic proteins (BDAPs).

Claim 21. (Currently amended) The angiogenic composition of claim 2 wherein said other at least one angiogenic ~~growth-factor~~ peptide comprises vascular endothelial cell growth factor (VEGF).

Claim 22. (Currently amended) The angiogenic composition of claim 2 wherein said other at least one angiogenic ~~growth-factor~~ peptide comprises at least one peptide chosen from the group consisting of IGD (SEQ ID NO:1), ~~GGIGDGG (SEQ ID NO:2)~~, IGDIGD (SEQ ID NO:3), cyclic IGDIGD (SEQ ID NO:4), IGDS (SEQ ID NO:5), and IGDQ (SEQ ID NO:6).

Claim 23. (Currently amended) The composition of claim 2, further comprising a pharmacologically acceptable carrier.

Claim 24. (Previously presented) The composition of claim 23 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.

Claim 25. (Previously presented) The composition of claim 23 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.

Claim 26. (Currently amended) The composition of claim 2, ~~comprising~~ wherein the composition is an injectable solution.

Claim 27. (Currently amended) The composition of claim 23, wherein the ~~injectable solution~~ composition further comprises polyvinylpyrrolidinone.

Claim 28. (Currently amended) The composition of claim 23, wherein the ~~injectable solution~~ composition further comprises hydrochloric acid.

Claim 29. (Currently amended) The angiogenic composition of claim 5, further comprising at least one angiogenic ~~growth factor~~ peptide other than said at least one peptide.

Claim 30. (Currently amended) The angiogenic composition of claim 29 wherein said at least one angiogenic ~~growth factor~~ peptide is chosen from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF- α), transforming growth factor-beta (TGF- β), and tumor necrosis factor-alpha (TNF- α).

Claim 31. (Currently amended) The angiogenic composition of claim 29 wherein said at least one angiogenic ~~growth factor~~ peptide comprises bone-derived angiogenic proteins (BDAPs).

Claim 32. (Currently amended) The angiogenic composition of claim 29 wherein said at least one angiogenic ~~growth factor~~ peptide comprises vascular endothelial cell growth factor (VEGF).

Claim 33. (Currently amended) The angiogenic composition of claim 29 wherein said at least one angiogenic ~~growth factor~~ peptide comprises at least one peptide chosen from the group consisting of IGD (SEQ ID NO:1), ~~GGIGDGG (SEQ ID NO:2)~~, IGDIGD (SEQ ID NO:3), cyclic IGDIGD (SEQ ID NO:4), IGDS (SEQ ID NO:5), and IGDQ (SEQ ID NO:6).

Claim 34. (Currently amended) The composition of claim 5, further comprising a pharmacologically acceptable carrier.

Claim 35. (Previously presented) The composition of claim 34 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.

Claim 36. (Previously presented) The composition of claim 34 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.

Claim 37. (Currently amended) The composition of claim 5, ~~comprising~~ wherein the composition is an injectable solution.

Claim 38. (Currently amended) The composition of claim 37, wherein the ~~injectable solution~~ composition further comprises polyvinylpyrrolidinone.

Claim 39. (Currently amended) The composition of claim 37, wherein the ~~injectable solution~~ composition further comprises hydrochloric acid.

Claim 40. (Previously presented) The angiogenic composition of claim 5 wherein said matrix comprises a cell growth promoting matrix.